Marian Severin Wettstein

Marian Severin Wettstein

Auto-generated profile, based on publicly available information

Marian Severin Wettstein

Division of Urology, Department of Surgery University of Toronto Toronto ON Canada

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
MUMartin Urner
Martin Urner
PJPeter Jüni
Peter Jüni
BHBettina Hansen
Bettina Hansen
MWMarian S Wettstein
Marian S Wettstein
NFNiall D Ferguson
Niall D Ferguson
EFEddy Fan
Eddy Fan

31 August 2015 in BJU International
Verified
Journal Article
Open access
PDF file
CPCédric Poyet
Cédric Poyet
DNDaan Nieboer
Daan Nieboer
BBBimal Bhindi
Bimal Bhindi
GKGirish S. Kulkarni
Girish S. Kulkarni
CWCaroline Wiederkehr
Caroline Wiederkehr
THThomas Hermanns
Thomas Hermanns
Objectives: To externally validate and compare the two novel versions of the European Randomised Study for Screening of Prostate Cancer ( ERSPC )‐prostate cancer risk calculator ( RC ) and Prostate Cancer Prevention Trial ( PCPT )‐ RC . Patients and Methods: All men who underwent a transrectal prostate biopsy in a European tertiary care centre between 2004 and 2012 were retrospectively identified. The probability of detecting prostate cancer and significant cancer (Gleason score ≥7) was calculated for each man using the novel versions of the ERSPC ‐ RC ( DRE ‐based version 3/4) and the PCPT ‐ RC (version 2.0) and compared with biopsy results. Calibration and discrimination were assessed using the calibration slope method and the area under the receiver operating characteristic curve ( AUC ), respectively. Additionally, decision curve analyses were performed. Results: Of 1 996 men, 483 (24%) were diagnosed with prostate cancer and 226 (11%) with significant prostate cancer. Calibration of the two RC s was comparable, although the PCPT ‐ RC was slightly superior in the higher risk prediction range for any and significant prostate cancer. Discrimination of the ERSPC ‐ and PCPT ‐ RC was comparable for any prostate cancer ( AUC s 0.65 vs 0.66), while the ERSPC ‐ RC was somewhat better for significant prostate cancer ( AUC s 0.73 vs 0.70). Decision curve analyses revealed a comparable net benefit for any prostate cancer and a slightly greater net benefit for significant prostate cancer using the ERSPC ‐ RC . Conclusions: In our independent external validation, both updated RC s showed less optimistic performance compared with their original reports, particularly for the prediction of any prostate cancer. Risk prediction of significant prostate cancer, which is important to avoid unnecessary biopsies and reduce over‐diagnosis and overtreatment, was better for both RC s and slightly superior using the ERSPC ‐ RC .

1 May 2020 in Journal of Urology
Verified
Journal Article
Closed access
CFChristian D. Fankhauser
Christian D. Fankhauser
JGJosias B. Grogg
Josias B. Grogg
SHStefanie Hayoz
Stefanie Hayoz
MWMarian S. Wettstein
Marian S. Wettstein
KDKlaus-Peter Dieckmann
Klaus-Peter Dieckmann
THThomas Hermanns
Thomas Hermanns
Aims:Leydig cell tumors (LCTs) are rare but the most common non-germ cell testicular tumors. Only limited evidence exists for reliably differentiating between benign and malignant LCTs and for opti...

10 December 2015 in British Journal of Cancer
Verified
Journal Article
Open access
BBBimal Bhindi
Bimal Bhindi
THThomas Hermanns
Thomas Hermanns
YWYanliang Wei
Yanliang Wei
JYJulie Yu
Julie Yu
PRPatrick O Richard
Patrick O Richard
GKGirish S Kulkarni
Girish S Kulkarni
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.

1 August 2018 in Journal of Urology
Verified
Journal Article
Open access
AMAshkan Mortezavi
Ashkan Mortezavi
OMOlivia Märzendorfer
Olivia Märzendorfer
ODOlivio F. Donati
Olivio F. Donati
GRGianluca Rizzi
Gianluca Rizzi
NRNiels J. Rupp
Niels J. Rupp
DEDaniel Eberli
Daniel Eberli
We evaluated the diagnostic accuracy of multiparametric magnetic resonance imaging and multiparametric magnetic resonance imaging/transrectal ultrasound fusion guided targeted biopsy against that of transperineal template saturation prostate biopsy to detect prostate cancer. We retrospectively analyzed the records of 415 men who consecutively presented for prostate biopsy between November 2014 and September 2016 at our tertiary care center. Multiparametric magnetic resonance imaging was performed using a 3 Tesla device without an endorectal coil, followed by transperineal template saturation prostate biopsy with the BiopSee® fusion system. Additional fusion guided targeted biopsy was done in men with a suspicious lesion on multiparametric magnetic resonance imaging, defined as Likert score 3 to 5. Any Gleason pattern 4 or greater was defined as clinically significant prostate cancer. The detection rates of multiparametric magnetic resonance imaging and fusion guided targeted biopsy were compared with the detection rate of transperineal template saturation prostate biopsy using the McNemar test. We obtained a median of 40 (range 30 to 55) and 3 (range 2 to 4) transperineal template saturation prostate biopsy and fusion guided targeted biopsy cores, respectively. Of the 124 patients (29.9%) without a suspicious lesion on multiparametric magnetic resonance imaging 32 (25.8%) were found to have clinically significant prostate cancer on transperineal template saturation prostate biopsy. Of the 291 patients (70.1%) with a Likert score of 3 to 5 clinically significant prostate cancer was detected in 129 (44.3%) by multiparametric magnetic resonance imaging fusion guided targeted biopsy, in 176 (60.5%) by transperineal template saturation prostate biopsy and in 187 (64.3%) by the combined approach. Overall 58 cases (19.9%) of clinically significant prostate cancer would have been missed if fusion guided targeted biopsy had been performed exclusively. The sensitivity of multiparametric magnetic resonance imaging and fusion guided targeted biopsy for clinically significant prostate cancer was 84.6% and 56.7% with a negative likelihood ratio of 0.35 and 0.46, respectively. Multiparametric magnetic resonance imaging alone should not be performed as a triage test due to a substantial number of false-negative cases with clinically significant prostate cancer. Systematic biopsy outperformed fusion guided targeted biopsy. Therefore, it will remain crucial in the diagnostic pathway of prostate cancer.

12 October 2015 in Disease Markers
Verified
Journal Article
Open access
PDF file
MWMarian S. Wettstein
Marian S. Wettstein
LBLorenz Buser
Lorenz Buser
THThomas Hermanns
Thomas Hermanns
FRFilip Roudnicky
Filip Roudnicky
DEDaniel Eberli
Daniel Eberli
CPCédric Poyet
Cédric Poyet
Aims. CD73 is a membrane associated 5′-ectonucleotidase that has been proposed as prognostic biomarker in various solid tumors. The aim of this study is to evaluate CD73 expression in a cohort of patients with primary bladder cancer in regard to its association with clinicopathological features and disease course.Methods. Tissue samples from 174 patients with a primary urothelial carcinoma were immunohistochemically assessed on a tissue microarray. Associations between CD73 expression and retrospectively obtained clinicopathological data were evaluated by contingency analysis. Survival analysis was performed to investigate the predictive value of CD73 within the subgroup of pTa and pT1 tumors in regard to progression-free survival (PFS).Results. High CD73 expression was found in 46 (26.4%) patients and was significantly associated with lower stage, lower grade, less adjacent carcinoma in situ and with lower Ki-67 proliferation index. High CD73 immunoreactivity in the subgroup of pTa and pT1 tumors(n=158)was significantly associated with longer PFS (HR: 0.228;p=0.047) in univariable Cox regression analysis.Conclusion. High CD73 immunoreactivity was associated with favorable clinicopathological features. Furthermore, it predicts better outcome in the subgroup of pTa and pT1 tumors and may thus serve as additional tool for the selection of patients with favorable prognosis.